我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
2
40.0%
招募中
3
60.0%
暂无批准数据
- Lasofoxifene demonstrates a strong tolerability profile and promising Ki67 suppression in a Phase 2 study, supporting further exploration in the neoadjuvant setting. - In premenopausal patients, early Ki67 suppression was observed without ovarian function suppression, suggesting a unique benefit for younger women with breast cancer. - The I-SPY 2 EOP study highlights lasofoxifene's significant activity in molecularly selected patients, showing potential in tumors predicted to have limited chemotherapy benefit. - Adverse events were mild, with hot flushes, constipation, fatigue, and nausea being the most common, indicating a favorable safety profile for lasofoxifene.
